801 REAPPRAISAL OF HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 EXPRESSION AFTER LONG-TERM FOLLOW-UP IN PATIENTS WITH PANCREATIC ADENOCARCINOMA TREATED WITH GEMCITABINE-BASED ADJUVANT CHEMOTHERAPY.

2020 ◽  
Vol 158 (6) ◽  
pp. S-1529-S-1530
Author(s):  
Naru Kondo ◽  
Kenichiro Uemura ◽  
Naoya Nakagawa ◽  
Kenjiro Okada ◽  
Shingo Seo ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Pancreatic Adenocarcinoma ◽  
Nucleoside Transporter ◽  
Equilibrative Nucleoside Transporter ◽  
Long Term Follow Up

Adjuvant chemotherapy for osteogenic sarcoma: Long-term follow-up from a single institution

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 9071-9071
Author(s):  
B. G. M. Hughes ◽  
N. Woodward ◽  
K. J. Lourigan ◽  
D. Humphreys ◽  
I. Dickenson ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Osteogenic Sarcoma ◽  
Single Institution ◽  
Long Term Follow Up

Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5509-5509 ◽  
Author(s):  
A. C. Swart
Keyword(s):  
Ovarian Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Adjuvant Treatment ◽  
Early Stage ◽  
Risk Groups ◽  
P Value ◽  
Long Term Follow Up

5509 Background: ICON1 and a meta-analysis of all relevant trials demonstrated an improvement in 5 year recurrence-free and overall survival (RFS and OS) for women with early-stage epithelial ovarian cancer (ES EOC) treated with adjuvant chemotherapy compared to no adjuvant chemotherapy. We aimed to determine if this initial benefit is maintained long-term and whether benefit is different with different risk groups of patients defined by stage, grade and histology. Method: 477 women with ES EOC were recruited from centres in Italy (271 women) UK (195) Switzerland (11) between August 1991 and January 2000. 5-year results were presented at ASCO 2001. Systematic long-term follow up was planned and completed in May 2006. Results: With a median follow-up of 9.2 years, 168 women have developed recurrent disease or died and 144 women have died. The Hazard Ratio (HR) for RFS of 0.70 in favour of adjuvant chemotherapy (95% CI 0.52–0.95 p= 0.023) translated into an improvement of 10-year absolute RFS of 10% from 57 to 67%. For OS, HR was 0.74 (95% CI 0.53–1.02 p= 0.066), a corresponding improvement in 10-year absolute OS of 8% from 64% to 72%. 26% of patients died from causes other than ovarian cancer. Stage I patients were grouped as low (Ia, grade 1), medium (Ia grade 2, Ib or Ic grade 1) and high risk (Ia, grade 3, Ib or IC grade 2 or 3, any clear cell). The test of interaction between risk groups and adjuvant treatment for RFS and OS was 0.055 and 0.13, respectively. The HR, 95%CI and p value are summarised in the table . Conclusions The long-term benefit of adjuvant treatment on RFS is confirmed. There is clear evidence that adjuvant chemotherapy reduces the risk of recurrence/death or death alone in high-risk patients but not in the low-risk group. [Table: see text] [Table: see text]

scholarly journals Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma

Cancer ◽  
1999 ◽  
Vol 85 (4) ◽  
pp. 899-904 ◽  
Author(s):  
Bahar Mikhak ◽  
Marianna Zahurak ◽  
Martin D. Abeloff ◽  
John H. Fetting ◽  
Nancy E. Davidson ◽  
...  
Keyword(s):  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Breast Carcinoma ◽  
Long Term Follow Up ◽  
High Risk Breast

Surgical treatment of pancreatic adenocarcinoma using cephalic duodenopancreatectomy (Part 2). Long term follow up after 204 cases

2010 ◽  
Vol 88 (6) ◽  
pp. 374-382
Author(s):  
Juan Fabregat ◽  
Juli Busquets ◽  
Núria Peláez ◽  
Rosa Jorba ◽  
Francisco García-Borobia ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Pancreatic Adenocarcinoma ◽  
Long Term Follow Up

Changing patterns of prognosticators during long-term follow-up of gastric cancer after D2–3 resection and adjuvant chemotherapy: 15-year follow-up at one Korean institution

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4050-4050
Author(s):  
H. C. Jeung ◽  
Y. W. Moon ◽  
S. Y. Rha ◽  
S. H. Noh ◽  
G. E. Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Survival Rates ◽  
Clear Cut ◽  
Stage Ib ◽  
Long Term Follow Up ◽  
Recurrence Patterns ◽  
Lost To Follow Up

4050 Background: Clinical outcome of long-term follow-up after 5 years of gastrectomy, such as recurrence or survival rate, recurrence patterns, and prognosticators, have not been studied well. We evaluated long-term natural history of gastric cancer with a median follow up duration of 15 years after D2–3 resection and adjuvant chemotherapy at a single institution. Especially in survived patients after 5 years of surgery, we analyzed risk factors for recurrence or survival. Methods: A total of 525 patients with stage IB to IVM0 (AJCC 2002) were accrued between 1984 and 1996. As a standard surgery, radical gastrectomy with D2–3 lymphadenectomy was performed. All the patients had adjuvant 5-FU plus adriamycin chemotherapy and 160 of them had also immunotherapy with poly A:U. Results: The median follow-up duration was 191 months. 15 patients (2.9%) were lost to follow-up with median follow-up of 45 months. 15-year disease-free and overall survival rates were 49.5% and 42.9%, respectively. In survivors after 5 years, recurrence rate was 16.0% (11.3% between 5 and 10 years; 4.7% after 10 years). The dominant recurrence patterns were distant metastasis (29.0%) between 5 and 10 years and secondary cancer (53.9%) after 10 years of surgery. Stage (IB vs II vs IIIA vs IIIB vs IVM0) was a clear-cut prognosticator during 5 years of gastrectomy, but its significance was lost between 5 to 10 years. At this time, only stage IVM0 was a significant poor prognosticator for gastric cancer-specific recurrence (HR = 6.61; P = 0.000) and cancer-specific death (HR = 7.04, P = 0.000). However, stage did not represent any significance after 10 years of surgery. Conclusions: In gastric carcinoma with D2–3 resection and adjuvant treatment, late recurrences after 5 years of surgery were not rare. Prognosticators were different in survivors after 5-years, 5–10 years and more than 10 years of surgery. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document